- Home
- EYEN vs TLSA Comparison
EYEN vs TLSA Comparison
Compare EYEN & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EYEN
- TLSA
- Stock Information
- Founded
- EYEN 2014
- TLSA 2013
- Country
- EYEN United States
- TLSA United Kingdom
- Employees
- EYEN N/A
- TLSA N/A
- Industry
- EYEN Biotechnology: Pharmaceutical Preparations
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- EYEN Health Care
- TLSA Health Care
- Exchange
- EYEN Nasdaq
- TLSA Nasdaq
- Market Cap
- EYEN 38.2M
- TLSA 87.8M
- IPO Year
- EYEN 2018
- TLSA 2000
- Fundamental
- Price
- EYEN $0.55
- TLSA $1.20
- Analyst Decision
- EYEN Strong Buy
- TLSA
- Analyst Count
- EYEN 2
- TLSA 0
- Target Price
- EYEN $12.00
- TLSA N/A
- AVG Volume (30 Days)
- EYEN 879.0K
- TLSA 145.8K
- Earning Date
- EYEN 11-11-2024
- TLSA 05-10-2024
- Dividend Yield
- EYEN N/A
- TLSA N/A
- EPS Growth
- EYEN N/A
- TLSA N/A
- EPS
- EYEN N/A
- TLSA N/A
- Revenue
- EYEN $31,405.00
- TLSA N/A
- Revenue This Year
- EYEN $50,309.30
- TLSA N/A
- Revenue Next Year
- EYEN $421.63
- TLSA N/A
- P/E Ratio
- EYEN N/A
- TLSA N/A
- Revenue Growth
- EYEN N/A
- TLSA N/A
- 52 Week Low
- EYEN $0.37
- TLSA $0.41
- 52 Week High
- EYEN $2.57
- TLSA $1.74
- Technical
- Relative Strength Index (RSI)
- EYEN 52.60
- TLSA 65.44
- Support Level
- EYEN $0.52
- TLSA $0.83
- Resistance Level
- EYEN $0.59
- TLSA $0.92
- Average True Range (ATR)
- EYEN 0.05
- TLSA 0.09
- MACD
- EYEN 0.01
- TLSA 0.03
- Stochastic Oscillator
- EYEN 66.45
- TLSA 84.52
About EYEN Eyenovia Inc.
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.